{
  "question": "Patient Clinical Profile:\nAge: 39 years old,Sex: M,Height: 171.6 cm,Body weight: 65 kg,BMI: 22.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 75%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.28,Albumin: 4.0 g/dL,Lymphocyte: 0.81,Neutrophil: 8.92,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
  "options": {
    "A": "Complete Response",
    "B": "Partial Response",
    "C": "Stable Disease",
    "D": "Progressive Disease"
  },
  "answer_idx": "B",
  "answer": "PR",
  "process_id": 491,
  "options_str": "A. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease",
  "gpt_filter_query": "<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 39 years old,Sex: M,Height: 171.6 cm,Body weight: 65 kg,BMI: 22.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 75%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.28,Albumin: 4.0 g/dL,Lymphocyte: 0.81,Neutrophil: 8.92,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nYou are an expert in filtering and evaluating multiple-choice questions for advanced reasoning tasks. Your job is to evaluate a given question and determine whether it meets the following criteria: \n1. **Depth of Reasoning:** The question should require deeper reasoning. If the question appears too simple, mark it as \"Too Simple\".\n2. **Unambiguous Correct Answer:** The question must have a unique and unambiguous correct answer. If the question asks for \"incorrect options\" or allows for multiple correct answers, mark it as \"Ambiguous Answer\".\n3. **Open-Ended Reformulation Feasibility:** The question should be suitable for reformatting into an open-ended format. If the question cannot be easily reformulated into an open-ended problem and a clear ground-truth answer, mark it as \"Not Reformulatable\".\n\nFor each question, provide one of the following evaluations:  \n- \"Pass\" (The question meets all the criteria.)  \n- \"Too Simple\"  \n- \"Ambiguous Answer\"  \n- \"Not Reformulatable\" ",
  "gpt_filter_response": "\"Pass\"",
  "gpt_reformat_query": "I will provide you with a multiple-choice question, and your task is to rewrite it into an open-ended question, along with a Ground-True Answer. The requirements are:\n\n1. The question must be specific, targeting the point being tested in the original multiple-choice question. Ensure it is open-ended, meaning no options are provided, but there must be a definitive Ground-True Answer.\n2. Based on the correct answer from the original question, provide a concise Ground-True Answer. The answer should allow for precise matching to determine whether the model's response is correct.\n\nHere is the multiple-choice question for you to rewrite:\n<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 39 years old,Sex: M,Height: 171.6 cm,Body weight: 65 kg,BMI: 22.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 75%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.28,Albumin: 4.0 g/dL,Lymphocyte: 0.81,Neutrophil: 8.92,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nPlease output the result in the following JSON format:\n```json\n{\n\"Open-ended Verifiable Question\": \"...\",\n\"Ground-True Answer\": \"...\"\n}\n```",
  "gpt_reformat_response": "```json\n{\n    \"Open-ended Verifiable Question\": \"Based on the patient clinical profile, including age, cancer stage, specific genetic mutations, and treatment regimen with Osimertinib, what is the most likely treatment response observed in this patient?\",\n    \"Ground-True Answer\": \"Partial Response\"\n}\n```",
  "Open-ended Verifiable Question": "Based on the patient clinical profile, including age, cancer stage, specific genetic mutations, and treatment regimen with Osimertinib, what is the most likely treatment response observed in this patient?",
  "Ground-True Answer": "Partial Response",
  "verify": [
    true
  ],
  "Long_CoT": [
    {
      "action": "Inner Thinking",
      "title": "Understanding Osimertinib",
      "content": "Osimertinib is a third-generation EGFR tyrosine kinase inhibitor commonly used to treat non-small cell lung cancer (NSCLC) patients who have specific mutations in the EGFR gene, such as the T790M mutation. It is often used in patients whose disease has progressed after treatment with earlier-generation EGFR inhibitors."
    },
    {
      "action": "Inner Thinking",
      "title": "Patient Genetic Profile",
      "content": "To assess the likely response to Osimertinib, it is critical to know if the patient has the EGFR T790M mutation, as this mutation is a primary indicator of response to the drug. Additionally, the presence of an activating EGFR mutation such as exon 19 deletion or L858R mutation makes the patient more likely to respond positively if resistance has developed to earlier treatments."
    },
    {
      "action": "Inner Thinking",
      "title": "Assessing Clinical Profile",
      "content": "The stage of cancer is also vital in understanding treatment response. Patients in early stages (stages I-II) may have differing responses compared to those in advanced stages (stages III-IV), with the latter often having a poorer prognosis. However, Osimertinib is primarily used for more advanced metastatic stages after detecting the T790M mutation post-resistance to earlier therapies."
    },
    {
      "action": "Inner Thinking",
      "title": "Effect of Age",
      "content": "Age is generally a factor that might influence overall treatment tolerance and side effects but is less critical in determining responsiveness to targeted therapies like Osimertinib, which primarily depend on genetic mutations."
    },
    {
      "action": "Inner Thinking",
      "title": "Expected Treatment Response",
      "content": "Given a patient with an EGFR mutation and evidence of progression after previous EGFR inhibitor therapy, and treatment with Osimertinib, the most likely response observed is a positive response such as a reduction in tumor size and stabilization of the disease. However, this is contingent on the presence of the T790M mutation."
    },
    {
      "action": "Final Conclusion",
      "content": "If the patient has confirmed EGFR T790M mutation and is on Osimertinib, the most likely treatment response is a positive one, characterized by tumor reduction and disease control."
    },
    {
      "action": "Verification",
      "content": "This conclusion is verified based on the established efficacy of Osimertinib in patients with the T790M mutation. Clinical trials like the AURA3 study have demonstrated significant response rates in such populations."
    }
  ],
  "gpt4_query_cot": [
    "<question>\nBased on the patient clinical profile, including age, cancer stage, specific genetic mutations, and treatment regimen with Osimertinib, what is the most likely treatment response observed in this patient?\n</question>\n\nPlease respond to the above question <question> using the Chain of Thought (CoT) reasoning method. Your response should consist of multiple steps, each of which includes three types of actions: **\"Inner Thinking\"**, **\"Final Conclusion\"**, and **\"Verification\"**:\n\n- **'Inner Thinking'**: This is the step where thinking is done. Note that multiple 'Inner Thinking' steps are required to describe thorough reasoning. Each step should first generate a brief title.\n- **'Final Conclusion'**: At this stage, you summarize the correct reasoning from previous 'Inner Thinking' steps and provide the final answer. No title is required here.\n- **'Verification'**: At this stage, you verify the conclusion from the \"Final Conclusion\" step. If the conclusion holds, end the process. If not, return to \"Inner Thinking\" for further reasoning. No title is required here.\n\nThe output format must strictly follow the JSON structure below:\n```json\n{\n\"CoT\": [\n    {\"action\": \"Inner Thinking\", \"title\": \"...\", \"content\": \"...\"},\n    ...,\n    {\"action\": \"Final Conclusion\", \"content\": \"...\"},\n    {\"action\": \"Verification\", \"content\": \"...\"}\n]\n}\n```",
    "<Model Response>  \nIf the patient has confirmed EGFR T790M mutation and is on Osimertinib, the most likely treatment response is a positive one, characterized by tumor reduction and disease control.  \n</Model Response>  \n\n<Reference Answer>  \nPartial Response\n</Reference Answer>  \n\nYou are provided with a model-generated response (<Model Response>) and a reference answer (<Reference Answer>). Compare the model response with the reference answer and determine its correctness. Your task is to simply output \"True\" if the response is correct, and \"False\" otherwise.",
    "<Thought Process>\n### Understanding Osimertinib\nOsimertinib is a third-generation EGFR tyrosine kinase inhibitor commonly used to treat non-small cell lung cancer (NSCLC) patients who have specific mutations in the EGFR gene, such as the T790M mutation. It is often used in patients whose disease has progressed after treatment with earlier-generation EGFR inhibitors.\n\n### Patient Genetic Profile\nTo assess the likely response to Osimertinib, it is critical to know if the patient has the EGFR T790M mutation, as this mutation is a primary indicator of response to the drug. Additionally, the presence of an activating EGFR mutation such as exon 19 deletion or L858R mutation makes the patient more likely to respond positively if resistance has developed to earlier treatments.\n\n### Assessing Clinical Profile\nThe stage of cancer is also vital in understanding treatment response. Patients in early stages (stages I-II) may have differing responses compared to those in advanced stages (stages III-IV), with the latter often having a poorer prognosis. However, Osimertinib is primarily used for more advanced metastatic stages after detecting the T790M mutation post-resistance to earlier therapies.\n\n### Effect of Age\nAge is generally a factor that might influence overall treatment tolerance and side effects but is less critical in determining responsiveness to targeted therapies like Osimertinib, which primarily depend on genetic mutations.\n\n### Expected Treatment Response\nGiven a patient with an EGFR mutation and evidence of progression after previous EGFR inhibitor therapy, and treatment with Osimertinib, the most likely response observed is a positive response such as a reduction in tumor size and stabilization of the disease. However, this is contingent on the presence of the T790M mutation.\n\n### Conclusion\nIf the patient has confirmed EGFR T790M mutation and is on Osimertinib, the most likely treatment response is a positive one, characterized by tumor reduction and disease control.\n\n### Verification\nThis conclusion is verified based on the established efficacy of Osimertinib in patients with the T790M mutation. Clinical trials like the AURA3 study have demonstrated significant response rates in such populations.\n</Thought Process>\n\n<Question>\nBased on the patient clinical profile, including age, cancer stage, specific genetic mutations, and treatment regimen with Osimertinib, what is the most likely treatment response observed in this patient?\n</Question>\n\nThe <Thought Process> above reflects the model's reasoning based on the <Question>. Your task is to rewrite the <Thought Process> to resemble a more human-like, intuitive natural thinking process. The new version should:\n\n1. Be presented as step-by-step reasoning, with each thought on a new line separated by a line break.\n2. Avoid structured titles or formatting, focusing on natural transitions. Use casual and natural language for transitions or validations, such as \"hmm,\" \"oh,\" \"also,\" or \"wait.\"\n3. Expand the content, making the reasoning richer, more detailed, and logically clear while still being conversational and intuitive.\n\nReturn directly the revised natural thinking in JSON format as follows:\n```json\n{\n  \"NaturalReasoning\": \"...\"\n}\n```",
    "<Internal Thinking>\nAlright, let's think about Osimertinib and what it does. So, this drug is actually a third-generation EGFR tyrosine kinase inhibitor. Basically, it's like a super targeted therapy for certain lung cancers—specifically non-small cell lung cancer or NSCLC. It's particularly handy for those cases where the cancer cells have a specific EGFR mutation, known as T790M. Hmm, isn't it fascinating how targeted cancer therapies are getting? Anyway, this medicine is usually given when the cancer has stopped responding to older types of EGFR inhibitors.\n\nNow, about the patient's genetic profile. It's super important to figure out if they have this EGFR T790M mutation because, without it, Osimertinib might not be very helpful. Plus, you also want to see if there are any other activating EGFR mutations, like the exon 19 deletion or L858R mutation. These usually mean a better response, especially if other treatments have stopped working.\n\nLet's see, what's the patient's cancer stage? That's crucial because the stage dictates how aggressive the treatment might need to be. Osimertinib is mostly used in later stages, like stage III or IV, especially if the cancer has spread after other treatments didn't work. And, obviously, if it's at an advanced stage, the treatment goals and expected outcomes might differ compared to earlier stages.\n\nOh, and age—a quick note on that. Age can make a difference in terms of how well a person might tolerate a treatment or the side effects they could experience. But when it comes to how effective Osimertinib is, age doesn't weigh in as much. It's all about those mutations!\n\nSo, thinking about this particular case—if the patient has this T790M mutation and they’ve moved on to Osimertinib after other treatments didn’t quite do the job, we’d expect a pretty positive response. Like, you might see tumors shrink or, at the very least, the disease might not be progressing as fast.\n\nThis conclusion isn't just pulled out of thin air. There’s solid evidence from clinical trials, like the AURA3 study, that shows good outcomes for people in this exact situation. It seems really promising when the right mutation is there. Makes you appreciate how much progress has been made in personalized medicine, right?\n</Internal Thinking>\n\n<Question>\nBased on the patient clinical profile, including age, cancer stage, specific genetic mutations, and treatment regimen with Osimertinib, what is the most likely treatment response observed in this patient?\n</Question>\n\nThe <Internal Thinking> represents your internal thoughts about the <Question>. Based on this, generate a rich and high-quality final response to the user. If there is a clear answer, provide it first. Ensure your final response closely follows the <Question>. The response style should resemble GPT-4's style as much as possible. Output only your final response, without any additional content."
  ],
  "gpt4_response_cot": [
    "```json\n{\n    \"CoT\": [\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Understanding Osimertinib\",\n            \"content\": \"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor commonly used to treat non-small cell lung cancer (NSCLC) patients who have specific mutations in the EGFR gene, such as the T790M mutation. It is often used in patients whose disease has progressed after treatment with earlier-generation EGFR inhibitors.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Patient Genetic Profile\",\n            \"content\": \"To assess the likely response to Osimertinib, it is critical to know if the patient has the EGFR T790M mutation, as this mutation is a primary indicator of response to the drug. Additionally, the presence of an activating EGFR mutation such as exon 19 deletion or L858R mutation makes the patient more likely to respond positively if resistance has developed to earlier treatments.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Assessing Clinical Profile\",\n            \"content\": \"The stage of cancer is also vital in understanding treatment response. Patients in early stages (stages I-II) may have differing responses compared to those in advanced stages (stages III-IV), with the latter often having a poorer prognosis. However, Osimertinib is primarily used for more advanced metastatic stages after detecting the T790M mutation post-resistance to earlier therapies.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Effect of Age\",\n            \"content\": \"Age is generally a factor that might influence overall treatment tolerance and side effects but is less critical in determining responsiveness to targeted therapies like Osimertinib, which primarily depend on genetic mutations.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Expected Treatment Response\",\n            \"content\": \"Given a patient with an EGFR mutation and evidence of progression after previous EGFR inhibitor therapy, and treatment with Osimertinib, the most likely response observed is a positive response such as a reduction in tumor size and stabilization of the disease. However, this is contingent on the presence of the T790M mutation.\"\n        },\n        {\n            \"action\": \"Final Conclusion\",\n            \"content\": \"If the patient has confirmed EGFR T790M mutation and is on Osimertinib, the most likely treatment response is a positive one, characterized by tumor reduction and disease control.\"\n        },\n        {\n            \"action\": \"Verification\",\n            \"content\": \"This conclusion is verified based on the established efficacy of Osimertinib in patients with the T790M mutation. Clinical trials like the AURA3 study have demonstrated significant response rates in such populations.\"\n        }\n    ]\n}\n```",
    "True",
    "```json\n{\n  \"NaturalReasoning\": \"Alright, let's think about Osimertinib and what it does. So, this drug is actually a third-generation EGFR tyrosine kinase inhibitor. Basically, it's like a super targeted therapy for certain lung cancers—specifically non-small cell lung cancer or NSCLC. It's particularly handy for those cases where the cancer cells have a specific EGFR mutation, known as T790M. Hmm, isn't it fascinating how targeted cancer therapies are getting? Anyway, this medicine is usually given when the cancer has stopped responding to older types of EGFR inhibitors.\\n\\nNow, about the patient's genetic profile. It's super important to figure out if they have this EGFR T790M mutation because, without it, Osimertinib might not be very helpful. Plus, you also want to see if there are any other activating EGFR mutations, like the exon 19 deletion or L858R mutation. These usually mean a better response, especially if other treatments have stopped working.\\n\\nLet's see, what's the patient's cancer stage? That's crucial because the stage dictates how aggressive the treatment might need to be. Osimertinib is mostly used in later stages, like stage III or IV, especially if the cancer has spread after other treatments didn't work. And, obviously, if it's at an advanced stage, the treatment goals and expected outcomes might differ compared to earlier stages.\\n\\nOh, and age—a quick note on that. Age can make a difference in terms of how well a person might tolerate a treatment or the side effects they could experience. But when it comes to how effective Osimertinib is, age doesn't weigh in as much. It's all about those mutations!\\n\\nSo, thinking about this particular case—if the patient has this T790M mutation and they’ve moved on to Osimertinib after other treatments didn’t quite do the job, we’d expect a pretty positive response. Like, you might see tumors shrink or, at the very least, the disease might not be progressing as fast.\\n\\nThis conclusion isn't just pulled out of thin air. There’s solid evidence from clinical trials, like the AURA3 study, that shows good outcomes for people in this exact situation. It seems really promising when the right mutation is there. Makes you appreciate how much progress has been made in personalized medicine, right?\"\n}\n```",
    "Based on the patient's clinical profile, if they have the EGFR T790M mutation and have progressed to Osimertinib treatment after other therapies have failed, the most likely treatment response is a reduction in tumor size or stabilization of the disease. Clinical trials, such as the AURA3 study, have demonstrated that patients with this specific mutation who receive Osimertinib often experience favorable outcomes, including tumor shrinkage and delayed disease progression. The patient's age might not significantly impact the efficacy of the treatment, but genetic mutations like T790M play a crucial role in the expected positive response to Osimertinib. This personalized approach validates the growing success of targeted cancer therapies."
  ],
  "response_struct": [
    [
      {
        "action": "Inner Thinking",
        "title": "Understanding Osimertinib",
        "content": "Osimertinib is a third-generation EGFR tyrosine kinase inhibitor commonly used to treat non-small cell lung cancer (NSCLC) patients who have specific mutations in the EGFR gene, such as the T790M mutation. It is often used in patients whose disease has progressed after treatment with earlier-generation EGFR inhibitors."
      },
      {
        "action": "Inner Thinking",
        "title": "Patient Genetic Profile",
        "content": "To assess the likely response to Osimertinib, it is critical to know if the patient has the EGFR T790M mutation, as this mutation is a primary indicator of response to the drug. Additionally, the presence of an activating EGFR mutation such as exon 19 deletion or L858R mutation makes the patient more likely to respond positively if resistance has developed to earlier treatments."
      },
      {
        "action": "Inner Thinking",
        "title": "Assessing Clinical Profile",
        "content": "The stage of cancer is also vital in understanding treatment response. Patients in early stages (stages I-II) may have differing responses compared to those in advanced stages (stages III-IV), with the latter often having a poorer prognosis. However, Osimertinib is primarily used for more advanced metastatic stages after detecting the T790M mutation post-resistance to earlier therapies."
      },
      {
        "action": "Inner Thinking",
        "title": "Effect of Age",
        "content": "Age is generally a factor that might influence overall treatment tolerance and side effects but is less critical in determining responsiveness to targeted therapies like Osimertinib, which primarily depend on genetic mutations."
      },
      {
        "action": "Inner Thinking",
        "title": "Expected Treatment Response",
        "content": "Given a patient with an EGFR mutation and evidence of progression after previous EGFR inhibitor therapy, and treatment with Osimertinib, the most likely response observed is a positive response such as a reduction in tumor size and stabilization of the disease. However, this is contingent on the presence of the T790M mutation."
      },
      {
        "action": "Final Conclusion",
        "content": "If the patient has confirmed EGFR T790M mutation and is on Osimertinib, the most likely treatment response is a positive one, characterized by tumor reduction and disease control."
      },
      {
        "action": "Verification",
        "content": "This conclusion is verified based on the established efficacy of Osimertinib in patients with the T790M mutation. Clinical trials like the AURA3 study have demonstrated significant response rates in such populations."
      }
    ]
  ],
  "response_type": [
    "Init_CoT"
  ],
  "prior_fail_try": [],
  "Complex_CoT": "Alright, let's think about Osimertinib and what it does. So, this drug is actually a third-generation EGFR tyrosine kinase inhibitor. Basically, it's like a super targeted therapy for certain lung cancers—specifically non-small cell lung cancer or NSCLC. It's particularly handy for those cases where the cancer cells have a specific EGFR mutation, known as T790M. Hmm, isn't it fascinating how targeted cancer therapies are getting? Anyway, this medicine is usually given when the cancer has stopped responding to older types of EGFR inhibitors.\n\nNow, about the patient's genetic profile. It's super important to figure out if they have this EGFR T790M mutation because, without it, Osimertinib might not be very helpful. Plus, you also want to see if there are any other activating EGFR mutations, like the exon 19 deletion or L858R mutation. These usually mean a better response, especially if other treatments have stopped working.\n\nLet's see, what's the patient's cancer stage? That's crucial because the stage dictates how aggressive the treatment might need to be. Osimertinib is mostly used in later stages, like stage III or IV, especially if the cancer has spread after other treatments didn't work. And, obviously, if it's at an advanced stage, the treatment goals and expected outcomes might differ compared to earlier stages.\n\nOh, and age—a quick note on that. Age can make a difference in terms of how well a person might tolerate a treatment or the side effects they could experience. But when it comes to how effective Osimertinib is, age doesn't weigh in as much. It's all about those mutations!\n\nSo, thinking about this particular case—if the patient has this T790M mutation and they’ve moved on to Osimertinib after other treatments didn’t quite do the job, we’d expect a pretty positive response. Like, you might see tumors shrink or, at the very least, the disease might not be progressing as fast.\n\nThis conclusion isn't just pulled out of thin air. There’s solid evidence from clinical trials, like the AURA3 study, that shows good outcomes for people in this exact situation. It seems really promising when the right mutation is there. Makes you appreciate how much progress has been made in personalized medicine, right?",
  "Response": "Based on the patient's clinical profile, if they have the EGFR T790M mutation and have progressed to Osimertinib treatment after other therapies have failed, the most likely treatment response is a reduction in tumor size or stabilization of the disease. Clinical trials, such as the AURA3 study, have demonstrated that patients with this specific mutation who receive Osimertinib often experience favorable outcomes, including tumor shrinkage and delayed disease progression. The patient's age might not significantly impact the efficacy of the treatment, but genetic mutations like T790M play a crucial role in the expected positive response to Osimertinib. This personalized approach validates the growing success of targeted cancer therapies.",
  "Question": "Based on the patient clinical profile, including age, cancer stage, specific genetic mutations, and treatment regimen with Osimertinib, what is the most likely treatment response observed in this patient?"
}